174 related articles for article (PubMed ID: 18158768)
41. In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia.
Récher C; Chopin M; Raffoux E; Pierron G; Poupon J; Sigaux F; Dombret H; Stern MH
Br J Haematol; 2002 May; 117(2):343-50. PubMed ID: 11972516
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of intratumoral chemotherapy using arsenic trioxide (As2O3) sustained release tablets for the treatment of neurogliocytoma in nude mice.
Zhao HB; Sun QX; Chen XF; Han DY; Zhao SG
Eur Rev Med Pharmacol Sci; 2014; 18(17):2453-9. PubMed ID: 25268089
[TBL] [Abstract][Full Text] [Related]
43. Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells.
Gui K; Zhang X; Chen F; Ge Z; Zhang S; Qi X; Sun J; Yu Z
Biomed Pharmacother; 2019 Mar; 111():751-764. PubMed ID: 30612000
[TBL] [Abstract][Full Text] [Related]
44. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
[TBL] [Abstract][Full Text] [Related]
45. Microbial synthesis of poly-3-hydroxybutyrate and its application as targeted drug delivery vehicle.
Althuri A; Mathew J; Sindhu R; Banerjee R; Pandey A; Binod P
Bioresour Technol; 2013 Oct; 145():290-6. PubMed ID: 23415943
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy.
Yang Z; Yang M; Peng J
Drug Dev Ind Pharm; 2008 Aug; 34(8):834-9. PubMed ID: 18622876
[TBL] [Abstract][Full Text] [Related]
47. Nanospheres-incorporated implantable hydrogel as a trans-tissue drug delivery system.
Ding D; Zhu Z; Li R; Li X; Wu W; Jiang X; Liu B
ACS Nano; 2011 Apr; 5(4):2520-34. PubMed ID: 21428432
[TBL] [Abstract][Full Text] [Related]
48. Synergistic effects of arsenic trioxide and radiation in osteosarcoma cells through the induction of both autophagy and apoptosis.
Chiu HW; Lin W; Ho SY; Wang YJ
Radiat Res; 2011 May; 175(5):547-60. PubMed ID: 21388295
[TBL] [Abstract][Full Text] [Related]
49. Localized Co-delivery of Doxorubicin, Cisplatin, and Methotrexate by Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
Ma H; He C; Cheng Y; Yang Z; Zang J; Liu J; Chen X
ACS Appl Mater Interfaces; 2015 Dec; 7(49):27040-8. PubMed ID: 26575336
[TBL] [Abstract][Full Text] [Related]
50. Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).
Li Y; Yu G; Li Q; Wang W; Shen X; Liu H; Liu R
PLoS One; 2015; 10(4):e0124959. PubMed ID: 25915411
[TBL] [Abstract][Full Text] [Related]
51. Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.
Liu Y; Yue J; Ren Z; He M; Wang A; Xie J; Li T; Liu G; He X; Ge S; Yuan Y; Yang L
Toxicol Appl Pharmacol; 2024 Jan; 482():116798. PubMed ID: 38160894
[TBL] [Abstract][Full Text] [Related]
52. Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging.
Zhao Z; Wang X; Zhang Z; Zhang H; Liu H; Zhu X; Li H; Chi X; Yin Z; Gao J
ACS Nano; 2015 Mar; 9(3):2749-59. PubMed ID: 25688714
[TBL] [Abstract][Full Text] [Related]
53. [Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo].
Lu J; Jin J
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):782-6. PubMed ID: 17229386
[TBL] [Abstract][Full Text] [Related]
54. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
55. Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: synthesis, antitumor efficiency in vivo and penetration in tumors.
Ding D; Zhu Z; Liu Q; Wang J; Hu Y; Jiang X; Liu B
Eur J Pharm Biopharm; 2011 Sep; 79(1):142-9. PubMed ID: 21272637
[TBL] [Abstract][Full Text] [Related]
56. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
57. A study on the thermochemotherapy effect of nanosized As2O3/MZF thermosensitive magnetoliposomes on experimental hepatoma in vitro and in vivo.
Wang L; Zhang J; An Y; Wang Z; Liu J; Li Y; Zhang D
Nanotechnology; 2011 Aug; 22(31):315102. PubMed ID: 21730756
[TBL] [Abstract][Full Text] [Related]
58. Anti-tumor efficacy of polymer-platinum(II) complex micelles fabricated from folate conjugated PEG-graft-α,β-poly [(N-amino acidyl)-aspartamide] and cis-dichlorodiammine platinum(II) in tumor-bearing mice.
Xue Y; Tang X; Huang J; Zhang X; Yu J; Zhang Y; Gui S
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):280-8. PubMed ID: 21435846
[TBL] [Abstract][Full Text] [Related]
59. Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study.
Chen FY; Yi JW; Gu ZJ; Tang BB; Li JQ; Li L; Kulkarni P; Liu L; Mason RP; Tang Q
Nanoscale; 2016 Mar; 8(11):6094-100. PubMed ID: 26932298
[TBL] [Abstract][Full Text] [Related]
60. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Rousselot P; Larghero J; Arnulf B; Poupon J; Royer B; Tibi A; Madelaine-Chambrin I; Cimerman P; Chevret S; Hermine O; Dombret H; Claude Brouet J; Paul Fermand J
Leukemia; 2004 Sep; 18(9):1518-21. PubMed ID: 15269785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
